Yahoo
KOSDAQ - Delayed Quote KRW

Rznomics Inc. (476830.KQ)

24,700.00 -400.00 (-1.59%)
At close: 3:30:28 PM GMT+9
Chart Range Bar
Loading chart for 476830.KQ
  • Previous Close 25,100.00
  • Open 24,700.00
  • Bid 24,850.00 x --
  • Ask 24,900.00 x --
  • Day's Range 24,150.00 - 26,300.00
  • 52 Week Range 19,990.00 - 122,625.00
  • Volume 383,893
  • Avg. Volume 337,142
  • Market Cap (intraday) 692.969B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si, South Korea.

www.rznomics.com

--

Full Time Employees

--

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/22/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

476830.KQ
69.22%
KOSPI Composite Index (^KS11)
31.31%

1-Year Return

476830.KQ
57.78%
KOSPI Composite Index (^KS11)
42.49%

3-Year Return

476830.KQ
57.78%
KOSPI Composite Index (^KS11)
133.00%

5-Year Return

476830.KQ
57.78%
KOSPI Composite Index (^KS11)
84.08%

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    716.82B

  • Enterprise Value

    682.59B

  • Trailing P/E

    5.63

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    357.74

  • Price/Book (mrq)

    15.38

  • Enterprise Value/Revenue

    340.66

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Mobilize your Website
View Site in Mobile | Classic
Share by: